Miscellaneous
Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider (2021) CME Available: https://auau.auanet.org/node/31450 ACKNOWLEDGEMENTS Support provided by independent educational grants from Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck, Pfizer, Inc. and Sanofi Genzyme. At the conclusion of the activity, participants will be able to: 1. Explain the mechanism of checkpoint inhibitors. 2. Describe historical and novel treatments for systemic prostate cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map. 3. Describe historical and novel treatments for systemic bladder cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map. 4. Describe historical and novel treatments for systemic kidney cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map.